

Supplementary information

Effect of novel triazole-amino acid hybrids on growth and virulence of

Candida species: *In vitro* and *in vivo* studies

Babita Aneja^{a,b,‡}, Mohammad Irfan^{a,c,‡}, Charu Kapil^d, Mohamad Aman Jairajpuri^d, Ronan Maguire^e, Kevin Kavanagh^e, **M. Moshahid A. Rizvi^f**, Nikhat Manzoor^{c,†,*}, Amir Azam^b, Mohammad Abid^{a,†,*}

^aMedicinal Chemistry Lab, Department of Biosciences, Jamia Millia Islamia (A Central University),
Jamia Nagar, New Delhi 110025, India

^bDepartment of Chemistry, Jamia Millia Islamia (A Central University), Jamia Nagar, New Delhi
110025, India

^cMedical Mycology Lab, Department of Biosciences, Jamia Millia Islamia (A Central University),
Jamia Nagar, New Delhi 110025, India

^dProtein Conformation and Enzymology Lab, Department of Biosciences, Jamia Millia Islamia (A
Central University), Jamia Nagar, New Delhi 110025, India

^eDepartment of Biology, Maynooth University, Co. Kildare, Ireland

^f **Genome-Biology Lab, Department of Biosciences, Jamia Millia Islamia (A Central University),
Jamia Nagar, New Delhi 110025, India**

‡ These authors contributed equally.

† Present address: M. Abid; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 68198-6805, USA. N. Manzoor; College of Applied Medical Sciences, Taibah University, Al-Madinah Al-Munawarah, KSA.

*Correspondence: M. Abid (mabid@jmi.ac.in) , N. Manzoor (nmanzoor@jmi.ac.in)

Table of contents

Spectral data of representative compounds.....	S2-S15
--	--------

1. Spectral data of representative compounds

1.1. (1-(3-(4-fluorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methyl 2-[(*tert*-butoxycarbonyl)amino]-3-phenylpropanoate (**44**)




Fig. S1. ¹H NMR spectrum




Fig. S2: ^{13}C NMR spectrum




Fig. S3: ESI-MS spectrum

1.2. (R)-(1-(3-(4-fluorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methyl 2-amino-3-phenylpropanoate (68)




Fig. S4: ¹H NMR spectrum




Fig. S5: ^{13}C NMR spectrum




Fig. S6: ESI-MS spectrum

1.3. (1-(3-(4-fluorobenzylamino)-3-oxopropyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-[(*tert*-butoxycarbonyl)amino]-3-(1*H*-indol-3-yl)propanoate (46)




Fig. S7: ¹H NMR spectrum




Fig. S8: ^{13}C NMR spectrum




Fig. S9: ESI-MS spectrum




Fig. S10: COSY spectrum




Fig. S11: HETCOR spectrum

1.4. (1-(3-(4-fluorobenzylamino)-3-oxopropyl)-1*H*-1,2,3-triazol-4-yl)methyl 2-amino-3-(1*H*-indol-3-yl)propanoate (70)




Fig. S12. ¹H NMR spectrum




Fig. S13: ^{13}C NMR spectrum




Fig. S14. ESI-MS spectrum